Trial · NCT00167219
Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)
NCT00167219, Phase 1, Phase 2, Completed, Masonic Cancer Center, University of Minnesota; results first posted 2023-11-07
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML). Trials, record NCT00167219. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00167219
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)
- NCT number
- NCT00167219
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 15 participants, actual
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Conditions
- Juvenile Myelomonocytic Leukemia
- Interventions
- Stem Cell Transplant, Preparative Regimen
- First posted
- 2005-09-14
- Last updated
- 2023-11-07
- Results first posted
- 2023-11-07
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Determine Probability of Long-term Disease Free Survival in JMML | at 1 year after transplant | |
| Secondary | Combined Incidence of Neutrophil Engraftment, Graft-versus-host Disease (GVHD), Regimen-related Toxicity, and Relapse. | at 1 year after transplant | Measured by AGVHD Grades 2 - 4. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Determine Probability of Long-term Disease Free Survival in JMML | at 1 year after transplant | Percentage of participants | NUMBER | |
| SECONDARY | Combined Incidence of Neutrophil Engraftment, Graft-versus-host Disease (GVHD), Regimen-related Toxicity, and Relapse. | at 1 year after transplant | Percentage of participants | NUMBER |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Determine Probability of Long-term Disease Free Survival in JMML | Intent-to-Treat | 67 | 95% Confidence Interval 38 to 85 | Percentage of participants | |
| Combined Incidence of Neutrophil Engraftment, Graft-versus-host Disease (GVHD), Regimen-related Toxicity, and Relapse. | Intent-to-Treat | 33 | 95% Confidence Interval 10 to 57 | Percentage of participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Intent-to-Treat | 15 | |
| Overall Study | COMPLETED | Intent-to-Treat | 15 | |
| Overall Study | NOT COMPLETED | Intent-to-Treat | 0 |
Source ClinicalTrials.gov
Adverse events23
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hypertension | Vascular disorders | Intent-to-Treat | 4 | 15 | 6 |
| other | Pericardial Effusion | Cardiac disorders | Intent-to-Treat | 4 | 15 | 4 |
| other | Blood in Stool | Gastrointestinal disorders | Intent-to-Treat | 4 | 15 | 5 |
| other | Blood in Urine | Gastrointestinal disorders | Intent-to-Treat | 1 | 15 | 1 |
| other | Rectal Bleed | Gastrointestinal disorders | Intent-to-Treat | 1 | 15 | 1 |
| other | Bowel Perferation | Gastrointestinal disorders | Intent-to-Treat | 1 | 15 | 1 |
| other | Colitis | Gastrointestinal disorders | Intent-to-Treat | 2 | 15 | 2 |
| other | Ischemia | Gastrointestinal disorders | Intent-to-Treat | 1 | 15 | 1 |
| other | Ascites | Gastrointestinal disorders | Intent-to-Treat | 2 | 15 | 2 |
| other | Vomiting | Gastrointestinal disorders | Intent-to-Treat | 1 | 15 | 1 |
1 to 10 of 23Source ClinicalTrials.gov
See all 23 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Intent-to-Treat | 4 | 15 |
| Total, other adverse events | Intent-to-Treat | 15 | 15 |
| Total, serious adverse events | Intent-to-Treat | 5 | 15 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00167219
GET https://conductscience.org/api/trials/v1/NCT00167219/events?page=2